{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "13",
                "@year": "2023",
                "@timestamp": "2023-07-13T01:13:22.000022-04:00",
                "@month": "07"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2021",
                "@month": "03"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": [
                {"xocs:funding-agency-matched-string": "Novartis Healthcare Pvt. Ltd."},
                {
                    "xocs:funding-agency-matched-string": "Bristol-Myers Squibb",
                    "xocs:funding-agency-acronym": "BMS",
                    "xocs:funding-agency": "Bristol-Myers Squibb",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100002491",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Eli Lilly",
                    "xocs:funding-agency": "Eli Lilly and Company",
                    "xocs:funding-id": "1473P",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004312",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Pfizer",
                    "xocs:funding-agency": "Pfizer",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004319",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "AstraZeneca",
                    "xocs:funding-agency": "AstraZeneca",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004325",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2635167/"
                },
                {
                    "xocs:funding-agency-matched-string": "GlaxoSmithKline",
                    "xocs:funding-agency-acronym": "GSK",
                    "xocs:funding-agency": "GlaxoSmithKline",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004330",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2635167/"
                },
                {
                    "xocs:funding-agency-matched-string": "Merck",
                    "xocs:funding-agency": "Merck",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004334",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Novartis",
                    "xocs:funding-agency": "Novartis",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004336",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2658434/"
                },
                {
                    "xocs:funding-agency-matched-string": "Roche",
                    "xocs:funding-agency": "Roche",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004337",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2658434/"
                },
                {
                    "xocs:funding-agency-matched-string": "Novartis Pharmaceuticals Corporation",
                    "xocs:funding-agency-acronym": "NPC",
                    "xocs:funding-agency": "Novartis Pharmaceuticals Corporation",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100008272",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Boehringer Ingelheim",
                    "xocs:funding-agency": "Boehringer Ingelheim",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100008349",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2921044/"
                },
                {
                    "xocs:funding-agency-matched-string": "Merck Sharp & Dohme",
                    "xocs:funding-agency-acronym": "MSD",
                    "xocs:funding-agency": "Merck Sharp and Dohme",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100009947",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2635167/"
                },
                {
                    "xocs:funding-agency-matched-string": "Prince of Songkla University",
                    "xocs:funding-agency-acronym": "PSU",
                    "xocs:funding-agency": "Prince of Songkla University",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100004508",
                    "xocs:funding-agency-country": "http://sws.geonames.org/1605651/"
                }
            ],
            "xocs:funding-addon-generated-timestamp": "2022-11-15T21:21:31.402Z",
            "xocs:funding-text": [
                {"$": "Disclosure: Dr. Tan reports receiving honoraria (self) from Novartis, Roche, Pfizer, Bristol-Myers Squibb, and Takeda; advisory or consultancy from Novartis, Merck, Loxo, AstraZeneca, Roche, and Pfizer; research grant or funding (institution) from Novartis, AstraZeneca, and GlaxoSmithKline; and travel or accommodation or expenses from Roche, Pfizer, and Boehringer Ingelheim. Dr. Geater reports advisory or consultancy from Boehringer Ingelheim; honoraria (self) from AstraZeneca and Boehringer Ingelheim; research grant or funding (institution) from AstraZeneca, Roche, Novartis, and Boehringer Ingelheim; and employment at the Prince of Songkla University. Dr. Yu reports advisory or consultancy from Roche, AstraZeneca, Ono Pharmaceutical, Boehringer Ingelheim, Novartis, GlaxoSmithKline, and Merck Sharp & Dohme; and research grant or funding (institution) from Novartis. Dr. Tsai reports receiving research grant or funding (institution) from Novartis; advisory or consultancy from Novartis, Pfizer, Roche, Eli Lilly, Merck Sharp & Dohme, Bristol-Myers Squibb, and AstraZeneca; and honoraria from Novartis, Pfizer, Roche, Eli Lilly, Merck Sharp & Dohme, Bristol-Myers Squibb, and AstraZeneca. Dr. Hsia reports advisory or consultancy from Novartis, Eli Lilly, AstraZeneca, and Roche; served as local speaker for Roche; and received research grant or funding (institution) from Novartis. Dr. Chen reports receiving research grant or funding (institution) from Novartis. Dr. Lin reports receiving research grant or funding (institution) from Novartis; and advisory or consultancy from AstraZeneca, Novartis, Boehringer Ingelheim, and Roche. Dr. Sriuranpong reports receiving research grant or funding (institution) from Novartis; honoraria (self) from Novartis; and advisory or consultancy from Novartis. Dr. Yang reports receiving research grant or funding (institution) from Novartis and advisory or consultancy from Novartis, Eli Lilly, AstraZeneca, Ono Pharmaceuticals, and Boehringer Ingelheim. Drs. Sen, Branle, and Shi report receiving shareholder or stockholder or stock options from Novartis and full-time employment at Novartis. Dr. Wu reports receiving honoraria (self) from AstraZeneca, Roche, Eli Lilly, Pfizer, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, and Sanofi; advisory or consultancy from AstraZeneca, Roche, and Boehringer Ingelheim; and research grant or funding (institution) from AstraZeneca, Roche, and Novartis. Dr. Lu declares no conflict of interest. Data from this study have been previously presented at the European Society for Medical Oncology (ESMO) 2019 congress (abstract #1473P) in Barcelona, Spain, September 27-October 01, 2019This study was sponsored by Novartis Pharmaceuticals Corporation. The authors thank the participating patients, their families, all study coinvestigators, and research coordinators. Medical writing support was provided by Gowri Natarajan and Shilpa Garg, Novartis Healthcare Pvt. Ltd. (Hyderabad, India). Drs. Tan and Wu contributed to study conception and design. Drs. Tan, Geater, Tsai, Lin, Yang, and Branle contributed to the collection and assembly of data. Drs. Tan, Geater, Yu, Tsai, Hsia, Chen, Lin, Lu, Sriuranpong, Yang, Sen, Branle, Shi, and Wu contributed to data analysis and interpretation. Drs. Tan, Geater, Yu, Tsai, Chen, Lin, Sriuranpong, and Yang contributed to the provision of study materials or patients. All authors contributed to manuscript writing and final approval of the manuscript."},
                {"$": "This study was sponsored by Novartis Pharmaceuticals Corporation . The authors thank the participating patients, their families, all study coinvestigators, and research coordinators. Medical writing support was provided by Gowri Natarajan and Shilpa Garg, Novartis Healthcare Pvt. Ltd. (Hyderabad, India). Drs. Tan and Wu contributed to study conception and design. Drs. Tan, Geater, Tsai, Lin, Yang, and Branle contributed to the collection and assembly of data. Drs. Tan, Geater, Yu, Tsai, Hsia, Chen, Lin, Lu, Sriuranpong, Yang, Sen, Branle, Shi, and Wu contributed to data analysis and interpretation. Drs. Tan, Geater, Yu, Tsai, Chen, Lin, Sriuranpong, and Yang contributed to the provision of study materials or patients. All authors contributed to manuscript writing and final approval of the manuscript."}
            ],
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Singapore",
                            "@afid": "60031809",
                            "@country": "sgp",
                            "organization": [
                                {"$": "Department of Medical Oncology"},
                                {"$": "National Cancer Centre Singapore"}
                            ],
                            "affiliation-id": {
                                "@afid": "60031809",
                                "@dptid": "112691924"
                            },
                            "@affiliation-instance-id": "S266636432030182X-2f9270fd089e1bf3a6417697d44d607a",
                            "ce:source-text": "Department of Medical Oncology, National Cancer Centre Singapore, Singapore",
                            "@dptid": "112691924"
                        },
                        "author": [{
                            "ce:given-name": "Daniel S.W.",
                            "preferred-name": {
                                "ce:given-name": "Daniel S.W.",
                                "ce:initials": "D.S.W.",
                                "ce:surname": "Tan",
                                "ce:indexed-name": "Tan D.S.W."
                            },
                            "@seq": "1",
                            "@author-instance-id": "S266636432030182X-e150cde7ae291a244ad3664b00e104c9",
                            "ce:initials": "D.S.W.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "BSc, M.B.B.S., MRCP, PhD",
                            "ce:surname": "Tan",
                            "@auid": "58314382700",
                            "ce:indexed-name": "Tan D.S.W."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60006314",
                            "@country": "tha",
                            "city": "Hat Yai",
                            "organization": [
                                {"$": "Department of Internal Medicine"},
                                {"$": "Prince of Songkla University"}
                            ],
                            "affiliation-id": {
                                "@afid": "60006314",
                                "@dptid": "112995643"
                            },
                            "@affiliation-instance-id": "S266636432030182X-ccaa0007bfd65d221ea98d7f2caa2e89",
                            "ce:source-text": "Department of Internal Medicine, Prince of Songkla University, Hat Yai, Thailand",
                            "@dptid": "112995643"
                        },
                        "author": [{
                            "ce:given-name": "Sarayut",
                            "preferred-name": {
                                "ce:given-name": "Sarayut",
                                "ce:initials": "S.",
                                "ce:surname": "Geater",
                                "ce:indexed-name": "Geater S."
                            },
                            "@seq": "2",
                            "@author-instance-id": "S266636432030182X-7dc9499e80e65b3ab725e28347d3ce56",
                            "ce:initials": "S.",
                            "@date-locked": "2021-11-09T01:17:32.356",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Geater",
                            "@auid": "16636219700",
                            "ce:indexed-name": "Geater S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Taiwan",
                            "@afid": "60073385",
                            "@country": "twn",
                            "city": "Taipei",
                            "organization": [
                                {"$": "Department of Internal Medicine"},
                                {"$": "National Taiwan University Hospital"}
                            ],
                            "affiliation-id": {"@afid": "60073385"},
                            "@affiliation-instance-id": "S266636432030182X-91c46551e1121d0b09931bd0b1be871a",
                            "ce:source-text": "Department of Internal Medicine, National Taiwan University Hospital, Taipei, Republic of China"
                        },
                        "author": [{
                            "ce:given-name": "Chong-Jen",
                            "preferred-name": {
                                "ce:given-name": "Chong Jen",
                                "ce:initials": "C.J.",
                                "ce:surname": "Yu",
                                "ce:indexed-name": "Yu C.J."
                            },
                            "@seq": "3",
                            "@author-instance-id": "S266636432030182X-d660d3591bf16e0eb1d9c7891856266e",
                            "ce:initials": "C.-J.",
                            "@date-locked": "2021-12-16T12:33:52.184",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD, PhD",
                            "ce:surname": "Yu",
                            "@auid": "7404977466",
                            "ce:indexed-name": "Yu C.-J."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Taiwan",
                            "@afid": "60013314",
                            "@country": "twn",
                            "city": "Taipei",
                            "organization": [
                                {"$": "Department of Oncology"},
                                {"$": "Taipei Veterans General Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "60013314",
                                "@dptid": "103695756"
                            },
                            "@affiliation-instance-id": "S266636432030182X-d1adb492938aa8d5119fb15e89e9066c",
                            "ce:source-text": "Department of Oncology, Taipei Veterans General Hospital, Taipei, Republic of China",
                            "@dptid": "103695756"
                        },
                        "author": [{
                            "ce:given-name": "Chun-Ming",
                            "preferred-name": {
                                "ce:given-name": "Chun Ming",
                                "ce:initials": "C.M.",
                                "ce:surname": "Tsai",
                                "ce:indexed-name": "Tsai C.M."
                            },
                            "@seq": "4",
                            "@author-instance-id": "S266636432030182X-2375d53c2557e11cb2530c631c36f563",
                            "ce:initials": "C.-M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Tsai",
                            "@auid": "7404967694",
                            "ce:indexed-name": "Tsai C.-M."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Taiwan",
                            "@afid": "60031941",
                            "@country": "twn",
                            "city": "Taichung",
                            "organization": [
                                {"$": "Department of Respiratory Therapy and Internal Medicine"},
                                {"$": "China Medical University Hospital"},
                                {"$": "China Medical University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60031941",
                                    "@dptid": "107081286"
                                },
                                {"@afid": "60006988"}
                            ],
                            "@affiliation-instance-id": "S266636432030182X-505ea91bab75e54a901aa09e46b89ca1",
                            "ce:source-text": "Department of Respiratory Therapy and Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Republic of China",
                            "@dptid": "107081286"
                        },
                        "author": [{
                            "ce:given-name": "Te-Chun",
                            "preferred-name": {
                                "ce:given-name": "Te Chun",
                                "ce:initials": "T.C.",
                                "ce:surname": "Hsia",
                                "ce:indexed-name": "Hsia T.C."
                            },
                            "@seq": "5",
                            "@author-instance-id": "S266636432030182X-faac4beae6cc067fa582b420c43a2f9b",
                            "ce:initials": "T.-C.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Hsia",
                            "@auid": "57221190351",
                            "ce:indexed-name": "Hsia T.-C."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "China",
                            "@afid": "60011715",
                            "@country": "chn",
                            "city": "Tianjin",
                            "organization": [
                                {"$": "Department of Lung Cancer Surgery"},
                                {"$": "Tianjin Medical University General Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "60011715",
                                "@dptid": "103626014"
                            },
                            "@affiliation-instance-id": "S266636432030182X-e0fd993f070b91973b17dea1bab2b20e",
                            "ce:source-text": "Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China",
                            "@dptid": "103626014"
                        },
                        "author": [{
                            "ce:given-name": "Jun",
                            "preferred-name": {
                                "ce:given-name": "Jun",
                                "ce:initials": "J.",
                                "ce:surname": "Chen",
                                "ce:indexed-name": "Chen J."
                            },
                            "@seq": "6",
                            "@author-instance-id": "S266636432030182X-6743779b8b8c15eafb2e7a9cbdd608d4",
                            "ce:initials": "J.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD, PhD",
                            "ce:surname": "Chen",
                            "@auid": "56214794800",
                            "ce:indexed-name": "Chen J."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Taiwan",
                            "@afid": "60031913",
                            "@country": "twn",
                            "city": "Kaohsiung",
                            "organization": [
                                {"$": "Department of Internal Medicine"},
                                {"$": "Kaohsiung Chang Gung Memorial Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "60031913",
                                "@dptid": "109849261"
                            },
                            "@affiliation-instance-id": "S266636432030182X-0adbae73587a430997ccbd7b5d99a9ed",
                            "ce:source-text": "Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Republic of China",
                            "@dptid": "109849261"
                        },
                        "author": [{
                            "ce:given-name": "Meng-Chih",
                            "preferred-name": {
                                "ce:given-name": "Meng Chih",
                                "ce:initials": "M.C.",
                                "ce:surname": "Lin",
                                "ce:indexed-name": "Lin M.C."
                            },
                            "@seq": "7",
                            "@author-instance-id": "S266636432030182X-4495c422e2222d17987c02eaa3b3229a",
                            "ce:initials": "M.-C.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Lin",
                            "@auid": "8233414100",
                            "ce:indexed-name": "Lin M.-C."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "China",
                            "@afid": "60073509",
                            "@country": "chn",
                            "city": "Chengdu",
                            "organization": [
                                {"$": "Department of Thoracic Oncology"},
                                {"$": "West China Hospital of Sichuan University"}
                            ],
                            "affiliation-id": {
                                "@afid": "60073509",
                                "@dptid": "104826015"
                            },
                            "@affiliation-instance-id": "S266636432030182X-614b248a635aa12adff5754a958c243c",
                            "ce:source-text": "Department of Thoracic Oncology, West China Hospital of Sichuan University, Chengdu, People's Republic of China",
                            "@dptid": "104826015"
                        },
                        "author": [{
                            "ce:given-name": "You",
                            "preferred-name": {
                                "ce:given-name": "You",
                                "ce:initials": "Y.",
                                "ce:surname": "Lu",
                                "ce:indexed-name": "Lu Y."
                            },
                            "@seq": "8",
                            "@author-instance-id": "S266636432030182X-bc70bf0dd8ab2b8907d37e756e76d864",
                            "ce:initials": "Y.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Lu",
                            "@auid": "57216627663",
                            "ce:indexed-name": "Lu Y."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60022183",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Chulalongkorn University and the King Chulalongkorn Memorial Hospital"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60022183",
                                    "@dptid": "100291259"
                                },
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "S266636432030182X-16b87056087d58a96cb22080e0b2a9bd",
                            "ce:source-text": "Department of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand",
                            "@dptid": "100291259"
                        },
                        "author": [{
                            "ce:given-name": "Virote",
                            "preferred-name": {
                                "ce:given-name": "Virote",
                                "ce:initials": "V.",
                                "ce:surname": "Sriuranpong",
                                "ce:indexed-name": "Sriuranpong V."
                            },
                            "@seq": "9",
                            "@author-instance-id": "S266636432030182X-22e218eaadcaddaa8706ccf781a93102",
                            "ce:initials": "V.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Sriuranpong",
                            "@auid": "6603599644",
                            "ce:indexed-name": "Sriuranpong V."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Taiwan",
                            "@afid": "60031913",
                            "@country": "twn",
                            "city": "Taoyuan",
                            "organization": [
                                {"$": "Department of Thoracic Medicine"},
                                {"$": "Chang Gung Memorial Hospital"}
                            ],
                            "affiliation-id": {
                                "@afid": "60031913",
                                "@dptid": "104621235"
                            },
                            "@affiliation-instance-id": "S266636432030182X-e980cea753c4b8256eff519fa1a78224",
                            "ce:source-text": "Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Republic of China",
                            "@dptid": "104621235"
                        },
                        "author": [{
                            "ce:given-name": "Cheng-Ta",
                            "preferred-name": {
                                "ce:given-name": "Cheng Ta",
                                "ce:initials": "C.T.",
                                "ce:surname": "Yang",
                                "ce:indexed-name": "Yang C.T."
                            },
                            "@seq": "10",
                            "@author-instance-id": "S266636432030182X-392bfe3212c790061a00c7fb36983384",
                            "ce:initials": "C.-T.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Yang",
                            "@auid": "8201458000",
                            "ce:indexed-name": "Yang C.-T."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009968",
                            "@country": "usa",
                            "city": "East Hanover",
                            "organization": {"$": "Novartis Pharmaceuticals Corporation"},
                            "affiliation-id": {"@afid": "60009968"},
                            "state": "NJ",
                            "@affiliation-instance-id": "S266636432030182X-6d88c9016adcc104084b7115ba8a7a40",
                            "ce:source-text": "Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"
                        },
                        "author": [
                            {
                                "ce:given-name": "Paramita",
                                "preferred-name": {
                                    "ce:given-name": "Paramita",
                                    "ce:initials": "P.",
                                    "ce:surname": "Sen",
                                    "ce:indexed-name": "Sen P."
                                },
                                "@seq": "11",
                                "@author-instance-id": "S266636432030182X-bb8f2d9dd836a90f3fcd1aad70f1bf1a",
                                "ce:initials": "P.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "PhD",
                                "ce:surname": "Sen",
                                "@auid": "55619668500",
                                "ce:indexed-name": "Sen P."
                            },
                            {
                                "ce:given-name": "Michael",
                                "preferred-name": {
                                    "ce:given-name": "Michael",
                                    "ce:initials": "M.",
                                    "ce:surname": "Shi",
                                    "ce:indexed-name": "Shi M."
                                },
                                "@seq": "13",
                                "@author-instance-id": "S266636432030182X-e4fd14de555bcde598287769efd86c7e",
                                "ce:initials": "M.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:degrees": "MD",
                                "ce:surname": "Shi",
                                "@auid": "57213819275",
                                "ce:indexed-name": "Shi M."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Switzerland",
                            "@afid": "60009968",
                            "@country": "che",
                            "city": "Basel",
                            "organization": {"$": "Novartis Pharma AG"},
                            "affiliation-id": {"@afid": "60009968"},
                            "@affiliation-instance-id": "S266636432030182X-24f429be5bd847521f53b22f8b6fe2d9",
                            "ce:source-text": "Novartis Pharma AG, Basel, Switzerland"
                        },
                        "author": [{
                            "ce:given-name": "Fabrice",
                            "preferred-name": {
                                "ce:given-name": "Fabrice",
                                "ce:initials": "F.",
                                "ce:surname": "Branle",
                                "ce:indexed-name": "Branle F."
                            },
                            "@seq": "12",
                            "@author-instance-id": "S266636432030182X-7a4f69d78af3f8aa74e4ca051caf2202",
                            "ce:initials": "F.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Branle",
                            "@auid": "23768207500",
                            "ce:indexed-name": "Branle F."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "China",
                            "@afid": "60069718",
                            "@country": "chn",
                            "city": "Guangzhou",
                            "organization": [
                                {"$": "Guangdong Lung Cancer Institute"},
                                {"$": "Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer"},
                                {"$": "Guangdong Provincial People's Hospital"}
                            ],
                            "affiliation-id": {"@afid": "60069718"},
                            "state": "Guangdong",
                            "@affiliation-instance-id": "S266636432030182X-c15d76283b58b074914522c9f3326abf",
                            "ce:source-text": "Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, People's Republic of China"
                        },
                        "author": [{
                            "ce:given-name": "Yi-Long",
                            "preferred-name": {
                                "ce:given-name": "Yi Long",
                                "ce:initials": "Y.L.",
                                "ce:surname": "Wu",
                                "ce:indexed-name": "Wu Y.L."
                            },
                            "@seq": "14",
                            "@author-instance-id": "S266636432030182X-2c01a99d72ed2f220b07916c36b94ce3",
                            "ce:initials": "Y.-L.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:degrees": "MD",
                            "ce:surname": "Wu",
                            "@auid": "57214815576",
                            "ce:indexed-name": "Wu Y.-L."
                        }]
                    }
                ],
                "citation-title": "Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis",
                "abstracts": "© 2020Introduction: In the phase 3 ASCEND-4 study, ceritinib exhibited improved progression-free survival (PFS) by Blinded Independent Review Committee (BIRC) assessment versus the standard first-line chemotherapy in patients with advanced ALK-rearranged NSCLC. Here, we assessed the efficacy and safety of ceritinib in the subgroup of Asian patients from the ASCEND-4 trial. Methods: Treatment-naive patients with stage IIIB or IV ALK-rearranged nonsquamous NSCLC were randomized in a one-to-one ratio to receive either oral ceritinib 750 mg/day (fasted) daily or intravenous chemotherapy ([cisplatin 75 mg/m2 or carboplatin area under the curve 5\u20136 plus pemetrexed 500 mg/m2] every three wk, followed by pemetrexed maintenance). The primary end point was PFS by BIRC assessment. Results: Of 376 randomized patients, 158 (42.0%) were Asian (ceritinib arm: N = 76; chemotherapy arm: N = 82). The median time from randomization to the cutoff date (June 24, 2016) was 18.3 months (range = 13.5\u201334.2) in the Asian subgroup. The median PFS (by BIRC assessment) was 26.3 months (95% confidence interval [CI]: 8.6\u2013not estimable) and 10.6 months (95% CI: 6.7\u201315.0), with an estimated 34% risk reduction in PFS (hazard ratio = 0.66, 95% CI: 0.41\u20131.05) in the ceritinib arm versus chemotherapy arm. The most common adverse events of any grade were diarrhea (85.5%), increased alanine aminotransferase and vomiting (73.7% each), and increased aspartate aminotransferase and nausea (69.7% each) in the ceritinib arm, and nausea (49.3%), vomiting (42.7%), and anemia (40.0%) in the chemotherapy arm. Conclusion: Ceritinib was effective and safe in treatment-naive Asian patients with advanced ALK-rearranged NSCLC. The findings were largely consistent with that of the overall study population.",
                "correspondence": {
                    "affiliation": {
                        "country": "Singapore",
                        "postal-code": "169610",
                        "@country": "sgp",
                        "organization": [
                            {"$": "Division of Medical Oncology"},
                            {"$": "National Cancer Centre Singapore"}
                        ]
                    },
                    "person": {
                        "ce:given-name": "Daniel S.W.",
                        "ce:initials": "D.S.W.",
                        "ce:degrees": "BSc, M.B.B.S., MRCP, PhD",
                        "ce:surname": "Tan",
                        "ce:indexed-name": "Tan D.S.W."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "ALK",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "ASCEND-4",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "Ceritinib",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "NSCLC",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "https://www.jtocrr.org/content/aims",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {"@xml:lang": "eng"},
                    "volisspag": {"voliss": {
                        "@volume": "2",
                        "@issue": "3"
                    }},
                    "@type": "j",
                    "sourcetitle": "JTO Clinical and Research Reports",
                    "publicationdate": {
                        "month": "03",
                        "year": "2021",
                        "date-text": "March 2021",
                        "day": "01"
                    },
                    "sourcetitle-abbrev": "JTO. Clin. Res. Rep.",
                    "@country": "usa",
                    "issn": {
                        "$": "26663643",
                        "@type": "electronic"
                    },
                    "publicationyear": {"@first": "2021"},
                    "publisher": {"publishername": "Elsevier Inc."},
                    "article-number": "100131",
                    "@srcid": "21101051861"
                },
                "enhancement": {"classificationgroup": {"classifications": [
                    {
                        "@type": "ASJC",
                        "classification": [
                            {"$": "2730"},
                            {"$": "2740"}
                        ]
                    },
                    {
                        "@type": "SUBJABBR",
                        "classification": "MEDI"
                    }
                ]}},
                "grantlist": {
                    "@complete": "y",
                    "grant-text": {
                        "$": "Disclosure: Dr. Tan reports receiving honoraria (self) from Novartis, Roche, Pfizer, Bristol-Myers Squibb, and Takeda; advisory or consultancy from Novartis, Merck, Loxo, AstraZeneca, Roche, and Pfizer; research grant or funding (institution) from Novartis, AstraZeneca, and GlaxoSmithKline; and travel or accommodation or expenses from Roche, Pfizer, and Boehringer Ingelheim. Dr. Geater reports advisory or consultancy from Boehringer Ingelheim; honoraria (self) from AstraZeneca and Boehringer Ingelheim; research grant or funding (institution) from AstraZeneca, Roche, Novartis, and Boehringer Ingelheim; and employment at the Prince of Songkla University. Dr. Yu reports advisory or consultancy from Roche, AstraZeneca, Ono Pharmaceutical, Boehringer Ingelheim, Novartis, GlaxoSmithKline, and Merck Sharp & Dohme; and research grant or funding (institution) from Novartis. Dr. Tsai reports receiving research grant or funding (institution) from Novartis; advisory or consultancy from Novartis, Pfizer, Roche, Eli Lilly, Merck Sharp & Dohme, Bristol-Myers Squibb, and AstraZeneca; and honoraria from Novartis, Pfizer, Roche, Eli Lilly, Merck Sharp & Dohme, Bristol-Myers Squibb, and AstraZeneca. Dr. Hsia reports advisory or consultancy from Novartis, Eli Lilly, AstraZeneca, and Roche; served as local speaker for Roche; and received research grant or funding (institution) from Novartis. Dr. Chen reports receiving research grant or funding (institution) from Novartis. Dr. Lin reports receiving research grant or funding (institution) from Novartis; and advisory or consultancy from AstraZeneca, Novartis, Boehringer Ingelheim, and Roche. Dr. Sriuranpong reports receiving research grant or funding (institution) from Novartis; honoraria (self) from Novartis; and advisory or consultancy from Novartis. Dr. Yang reports receiving research grant or funding (institution) from Novartis and advisory or consultancy from Novartis, Eli Lilly, AstraZeneca, Ono Pharmaceuticals, and Boehringer Ingelheim. Drs. Sen, Branle, and Shi report receiving shareholder or stockholder or stock options from Novartis and full-time employment at Novartis. Dr. Wu reports receiving honoraria (self) from AstraZeneca, Roche, Eli Lilly, Pfizer, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, and Sanofi; advisory or consultancy from AstraZeneca, Roche, and Boehringer Ingelheim; and research grant or funding (institution) from AstraZeneca, Roche, and Novartis. Dr. Lu declares no conflict of interest. Data from this study have been previously presented at the European Society for Medical Oncology (ESMO) 2019 congress (abstract #1473P) in Barcelona, Spain, September 27-October 01, 2019This study was sponsored by Novartis Pharmaceuticals Corporation. The authors thank the participating patients, their families, all study coinvestigators, and research coordinators. Medical writing support was provided by Gowri Natarajan and Shilpa Garg, Novartis Healthcare Pvt. Ltd. (Hyderabad, India). Drs. Tan and Wu contributed to study conception and design. Drs. Tan, Geater, Tsai, Lin, Yang, and Branle contributed to the collection and assembly of data. Drs. Tan, Geater, Yu, Tsai, Hsia, Chen, Lin, Lu, Sriuranpong, Yang, Sen, Branle, Shi, and Wu contributed to data analysis and interpretation. Drs. Tan, Geater, Yu, Tsai, Chen, Lin, Sriuranpong, and Yang contributed to the provision of study materials or patients. All authors contributed to manuscript writing and final approval of the manuscript.",
                        "@xml:lang": "eng"
                    },
                    "grant": [
                        {
                            "grant-acronym": "GSK",
                            "grant-agency": {
                                "@iso-code": "gbr",
                                "$": "GlaxoSmithKline"
                            },
                            "grant-agency-id": "100004330"
                        },
                        {
                            "grant-acronym": "NPC",
                            "grant-agency": {
                                "@iso-code": "usa",
                                "$": "Novartis Pharmaceuticals Corporation"
                            },
                            "grant-agency-id": "100008272"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "gbr",
                                "$": "AstraZeneca"
                            },
                            "grant-agency-id": "100004325"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "gbr",
                                "$": "AstraZeneca"
                            },
                            "grant-agency-id": "100004325"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "gbr",
                                "$": "AstraZeneca"
                            },
                            "grant-agency-id": "100004325"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Novartis"
                            },
                            "grant-agency-id": "100004336"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Roche"
                            },
                            "grant-agency-id": "100004337"
                        },
                        {
                            "grant-agency": {
                                "@iso-code": "che",
                                "$": "Roche"
                            },
                            "grant-agency-id": "100004337"
                        }
                    ]
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2021 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "dbcollection": [
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "16",
                    "@year": "2021",
                    "@timestamp": "BST 12:18:52",
                    "@month": "07"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2010876578",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "934322246",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20212740903",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20212349088",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "85109827725",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85109827725",
                            "@idtype": "SGR"
                        }
                    ],
                    "ce:pii": "S266636432030182X",
                    "ce:ern": "pii:S266636432030182X",
                    "ce:doi": "10.1016/j.jtocrr.2020.100131"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "27",
                "reference": [
                    {
                        "ref-fulltext": "Kwak, E.L., Bang, Y.J., Camidge, D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 (2010), 1693\u20131703.",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib1",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "78049425319",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "363"},
                                "pagerange": {
                                    "@first": "1693",
                                    "@last": "1703"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Kwak",
                                        "ce:indexed-name": "Kwak E.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Bang",
                                        "ce:indexed-name": "Bang Y.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Camidge",
                                        "ce:indexed-name": "Camidge D.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703."
                    },
                    {
                        "ref-fulltext": "Rikova, K., Guo, A., Zeng, Q., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (2007), 1190\u20131203.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2007"},
                            "ref-title": {"ref-titletext": "Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib2",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "36849065315",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "131"},
                                "pagerange": {
                                    "@first": "1190",
                                    "@last": "1203"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Rikova",
                                        "ce:indexed-name": "Rikova K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Guo",
                                        "ce:indexed-name": "Guo A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Zeng",
                                        "ce:indexed-name": "Zeng Q."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cell"
                        },
                        "ce:source-text": "Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190-1203."
                    },
                    {
                        "ref-fulltext": "Shaw, A.T., Yeap, B.Y., Mino-Kenudson, M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27 (2009), 4247\u20134253.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2009"},
                            "ref-title": {"ref-titletext": "Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib3",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "70349336416",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "27"},
                                "pagerange": {
                                    "@first": "4247",
                                    "@last": "4253"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Shaw",
                                        "ce:indexed-name": "Shaw A.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Yeap",
                                        "ce:indexed-name": "Yeap B.Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Mino-Kenudson",
                                        "ce:indexed-name": "Mino-Kenudson M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247-4253."
                    },
                    {
                        "ref-fulltext": "Soda, M., Choi, Y.L., Enomoto, M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561\u2013566.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2007"},
                            "ref-title": {"ref-titletext": "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib4",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "34547638047",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "448"},
                                "pagerange": {
                                    "@first": "561",
                                    "@last": "566"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Soda",
                                        "ce:indexed-name": "Soda M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Choi",
                                        "ce:indexed-name": "Choi Y.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Enomoto",
                                        "ce:indexed-name": "Enomoto M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nature"
                        },
                        "ce:source-text": "Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566."
                    },
                    {
                        "ref-fulltext": "Shaw, A.T., Gandhi, L., Gadgeel, S., et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17 (2016), 234\u2013242.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib5",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84959324643",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "17"},
                                "pagerange": {
                                    "@first": "234",
                                    "@last": "242"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Shaw",
                                        "ce:indexed-name": "Shaw A.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Gandhi",
                                        "ce:indexed-name": "Gandhi L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Gadgeel",
                                        "ce:indexed-name": "Gadgeel S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17:234-242."
                    },
                    {
                        "ref-fulltext": "Shaw, A.T., Kim, D.W., Mehra, R., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370 (2014), 1189\u20131197.",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Ceritinib in ALK-rearranged non-small-cell lung cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib6",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84896957081",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "370"},
                                "pagerange": {
                                    "@first": "1189",
                                    "@last": "1197"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Shaw",
                                        "ce:indexed-name": "Shaw A.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim D.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Mehra",
                                        "ce:indexed-name": "Mehra R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189-1197."
                    },
                    {
                        "ref-fulltext": "Shaw, A.T., Kim, D.W., Nakagawa, K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385\u20132394.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Crizotinib versus chemotherapy in advanced ALK-positive lung cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib7",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84879071011",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "368"},
                                "pagerange": {
                                    "@first": "2385",
                                    "@last": "2394"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Shaw",
                                        "ce:indexed-name": "Shaw A.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim D.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Nakagawa",
                                        "ce:indexed-name": "Nakagawa K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-2394."
                    },
                    {
                        "ref-fulltext": "Awad, M.M., Shaw, A.T., ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 12 (2014), 429\u2013439.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "ALK inhibitors in non-small cell lung cancer: crizotinib and beyond"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib8",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84905190188",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "12"},
                                "pagerange": {
                                    "@first": "429",
                                    "@last": "439"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.M.",
                                    "@_fa": "true",
                                    "ce:surname": "Awad",
                                    "ce:indexed-name": "Awad M.M."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.T.",
                                    "@_fa": "true",
                                    "ce:surname": "Shaw",
                                    "ce:indexed-name": "Shaw A.T."
                                }
                            ]},
                            "ref-sourcetitle": "Clin Adv Hematol Oncol"
                        },
                        "ce:source-text": "Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12:429-439."
                    },
                    {
                        "ref-fulltext": "Song, Z., Wang, M., Zhang, A., Alectinib:. a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically acquired resistance. Acta PharmSin B 5 (2015), 34\u201337.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Alectinib:. a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically acquired resistance"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib9",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84945189935",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "5"},
                                "pagerange": {
                                    "@first": "34",
                                    "@last": "37"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "Z.",
                                    "@_fa": "true",
                                    "ce:surname": "Song",
                                    "ce:indexed-name": "Song Z."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.",
                                    "@_fa": "true",
                                    "ce:surname": "Wang",
                                    "ce:indexed-name": "Wang M."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Zhang",
                                    "ce:indexed-name": "Zhang A."
                                }
                            ]},
                            "ref-sourcetitle": "Acta PharmSin B"
                        },
                        "ce:source-text": "Song Z, Wang M, Zhang A. Alectinib:. a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically acquired resistance. Acta PharmSin B. 2015;5:34-37."
                    },
                    {
                        "ref-fulltext": "Khozin, S., Blumenthal, G.M., Zhang, L., et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 21 (2015), 2436\u20132439.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib10",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84937116601",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "21"},
                                "pagerange": {
                                    "@first": "2436",
                                    "@last": "2439"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Khozin",
                                        "ce:indexed-name": "Khozin S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Blumenthal",
                                        "ce:indexed-name": "Blumenthal G.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21:2436-2439."
                    },
                    {
                        "ref-fulltext": "US Food and Drug Administration. FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-ceritinib-indication-previously-untreated-alk-positive-metastatic-NSCLC. (Accessed 19 June 2020)",
                        "@id": "11",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-ceritinib-indication-previously-untreated-alk-positive-metastatic-NSCLC",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib11",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85042801648",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "(Accessed 19 June 2020)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "US Food and Drug Administration",
                                "ce:indexed-name": "US Food and Drug Administration"
                            }}
                        },
                        "ce:source-text": "US Food and Drug Administration. FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-ceritinib-indication-previously-untreated-alk-positive-metastatic-NSCLC. Accessed June 19, 2020."
                    },
                    {
                        "ref-fulltext": "US Food and Drug Administration. Zykadia prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. (Accessed 1 July 2020)",
                        "@id": "12",
                        "ref-info": {
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf",
                                "@type": "email"
                            }},
                            "ref-title": {"ref-titletext": "Zykadia prescribing information"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib12",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85051505284",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "(Accessed 1 July 2020)",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "US Food and Drug Administration",
                                "ce:indexed-name": "US Food and Drug Administration"
                            }}
                        },
                        "ce:source-text": "US Food and Drug Administration. Zykadia prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Accessed July 1, 2020."
                    },
                    {
                        "ref-fulltext": "Kim, D.W., Mehra, R., Tan, D.S.W., et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 17 (2016), 452\u2013463.",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib13",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84960194194",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "17"},
                                "pagerange": {
                                    "@first": "452",
                                    "@last": "463"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim D.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Mehra",
                                        "ce:indexed-name": "Mehra R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.S.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Tan",
                                        "ce:indexed-name": "Tan D.S.W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Kim DW, Mehra R, Tan DSW, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17:452-463."
                    },
                    {
                        "ref-fulltext": "Nishio, M., Felip, E., Orlov, S., et al. Final overall survival and other efficacy and safety results from ASCEND-3: Phase II study of ceritinib in ALKi-naive patients with ALK-rearranged NSCLC. J Thorac Oncol 15 (2020), 609\u2013617.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Final overall survival and other efficacy and safety results from ASCEND-3: Phase II study of ceritinib in ALKi-naive patients with ALK-rearranged NSCLC"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib14",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85078128722",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "15"},
                                "pagerange": {
                                    "@first": "609",
                                    "@last": "617"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Nishio",
                                        "ce:indexed-name": "Nishio M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Felip",
                                        "ce:indexed-name": "Felip E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Orlov",
                                        "ce:indexed-name": "Orlov S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Thorac Oncol"
                        },
                        "ce:source-text": "Nishio M, Felip E, Orlov S, et al. Final overall survival and other efficacy and safety results from ASCEND-3: Phase II study of ceritinib in ALKi-naive patients with ALK-rearranged NSCLC. J Thorac Oncol. 2020;15:609-617."
                    },
                    {
                        "ref-fulltext": "Soria, J.C., Tan, D.S.W., Chiari, R., et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389 (2017), 917\u2013929.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib15",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85010189205",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "389"},
                                "pagerange": {
                                    "@first": "917",
                                    "@last": "929"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Soria",
                                        "ce:indexed-name": "Soria J.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.S.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Tan",
                                        "ce:indexed-name": "Tan D.S.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Chiari",
                                        "ce:indexed-name": "Chiari R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389:917-929."
                    },
                    {
                        "ref-fulltext": "Scagliotti, G.V., Kortsik, C., Dark, G.G., et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11 (2005), 690\u2013696.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2005"},
                            "ref-title": {"ref-titletext": "Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib16",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "19944426696",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "11"},
                                "pagerange": {
                                    "@first": "690",
                                    "@last": "696"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Scagliotti",
                                        "ce:indexed-name": "Scagliotti G.V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Kortsik",
                                        "ce:indexed-name": "Kortsik C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Dark",
                                        "ce:indexed-name": "Dark G.G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005;11:690-696."
                    },
                    {
                        "ref-fulltext": "Scagliotti, G.V., Parikh, P., von Pawel, J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (2008), 3543\u20133551.",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "ref-title": {"ref-titletext": "Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib17",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "49049089802",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "26"},
                                "pagerange": {
                                    "@first": "3543",
                                    "@last": "3551"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Scagliotti",
                                        "ce:indexed-name": "Scagliotti G.V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Parikh",
                                        "ce:indexed-name": "Parikh P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "von Pawel",
                                        "ce:indexed-name": "von Pawel J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551."
                    },
                    {
                        "ref-fulltext": "Brookmeyer, R., Crowley, J., A confidence interval for the median survival time. Biometrics 38 (1982), 29\u201341.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "1982"},
                            "ref-title": {"ref-titletext": "A confidence interval for the median survival time"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib18",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "0002429117",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "38"},
                                "pagerange": {
                                    "@first": "29",
                                    "@last": "41"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "R.",
                                    "@_fa": "true",
                                    "ce:surname": "Brookmeyer",
                                    "ce:indexed-name": "Brookmeyer R."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Crowley",
                                    "ce:indexed-name": "Crowley J."
                                }
                            ]},
                            "ref-sourcetitle": "Biometrics"
                        },
                        "ce:source-text": "Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29-41."
                    },
                    {
                        "ref-fulltext": "Huang, S.H., Huang, A.C., Wang, C.C., et al. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: the role of systemic progression control. Thorac Cancer 10 (2019), 2274\u20132281.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: the role of systemic progression control"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib19",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85074476985",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "10"},
                                "pagerange": {
                                    "@first": "2274",
                                    "@last": "2281"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Huang",
                                        "ce:indexed-name": "Huang S.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Huang",
                                        "ce:indexed-name": "Huang A.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang C.C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Thorac Cancer"
                        },
                        "ce:source-text": "Huang SH, Huang AC, Wang CC, et al. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: the role of systemic progression control. Thorac Cancer. 2019;10:2274-2281."
                    },
                    {
                        "ref-fulltext": "Zhou, C., Kim, S.W., Reungwetwattana, T., et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med 7 (2019), 437\u2013446.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib20",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85064705621",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "7"},
                                "pagerange": {
                                    "@first": "437",
                                    "@last": "446"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhou",
                                        "ce:indexed-name": "Zhou C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim S.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Reungwetwattana",
                                        "ce:indexed-name": "Reungwetwattana T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Respir Med"
                        },
                        "ce:source-text": "Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019;7:437-446."
                    },
                    {
                        "ref-fulltext": "Mok, T.S.K., Peters, S., Camidge, D.R., et al. Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study. Ann Oncol, 28(suppl 10), 2017, x191.",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib21",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85054844856",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "28"},
                                "pagerange": {"@first": "x191"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.S.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Mok",
                                        "ce:indexed-name": "Mok T.S.K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Peters",
                                        "ce:indexed-name": "Peters S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Camidge",
                                        "ce:indexed-name": "Camidge D.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Ann Oncol"
                        },
                        "ce:source-text": "Mok TSK, Peters S, Camidge DR, et al. Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study. Ann Oncol. 2017;28(suppl 10):x186-x195."
                    },
                    {
                        "ref-fulltext": "Wu, Y.L., Lu, S., Lu, Y., et al. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol 13 (2018), 1539\u20131548.",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib22",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85051792172",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "13"},
                                "pagerange": {
                                    "@first": "1539",
                                    "@last": "1548"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Wu",
                                        "ce:indexed-name": "Wu Y.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Lu",
                                        "ce:indexed-name": "Lu S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Lu",
                                        "ce:indexed-name": "Lu Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Thorac Oncol"
                        },
                        "ce:source-text": "Wu YL, Lu S, Lu Y, et al. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol. 2018;13:1539-1548."
                    },
                    {
                        "ref-fulltext": "Nishio, M., Kim, D.W., Wu, Y.L., et al. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat 50 (2018), 691\u2013700.",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib23",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85049774750",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "50"},
                                "pagerange": {
                                    "@first": "691",
                                    "@last": "700"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Nishio",
                                        "ce:indexed-name": "Nishio M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim D.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Wu",
                                        "ce:indexed-name": "Wu Y.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Res Treat"
                        },
                        "ce:source-text": "Nishio M, Kim DW, Wu YL, et al. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat. 2018;50:691-700."
                    },
                    {
                        "ref-fulltext": "Cho, B.C., Kim, D.W., Bearz, A., et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 12 (2017), 1357\u20131367.",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib24",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85028315202",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "12"},
                                "pagerange": {
                                    "@first": "1357",
                                    "@last": "1367"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Cho",
                                        "ce:indexed-name": "Cho B.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Kim",
                                        "ce:indexed-name": "Kim D.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bearz",
                                        "ce:indexed-name": "Bearz A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Thorac Oncol"
                        },
                        "ce:source-text": "Cho BC, Kim DW, Bearz A, et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017;12:1357-1367."
                    },
                    {
                        "ref-fulltext": "Cho, B.C., Obermannova, R., Bearz, A., et al. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC: primary efficacy results from the ASCEND-8 study. J Thorac Oncol 14 (2019), 1255\u20131265.",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC: primary efficacy results from the ASCEND-8 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib25",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85064602235",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "14"},
                                "pagerange": {
                                    "@first": "1255",
                                    "@last": "1265"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Cho",
                                        "ce:indexed-name": "Cho B.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Obermannova",
                                        "ce:indexed-name": "Obermannova R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Bearz",
                                        "ce:indexed-name": "Bearz A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Thorac Oncol"
                        },
                        "ce:source-text": "Cho BC, Obermannova R, Bearz A, et al. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC: primary efficacy results from the ASCEND-8 study. J Thorac Oncol. 2019;14:1255-1265."
                    },
                    {
                        "ref-fulltext": "Otoukesh, S., Sanchez, T., Mirshahidi, S., Wallace, D., Mirshahidi, H., ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: a clinical perspective. Cancer Treat Res Commun, 20, 2019, 100149.",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: a clinical perspective"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib26",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85065126940",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "20"},
                                "pagerange": {"@first": "100149"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Otoukesh",
                                    "ce:indexed-name": "Otoukesh S."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "T.",
                                    "@_fa": "true",
                                    "ce:surname": "Sanchez",
                                    "ce:indexed-name": "Sanchez T."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "S.",
                                    "@_fa": "true",
                                    "ce:surname": "Mirshahidi",
                                    "ce:indexed-name": "Mirshahidi S."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "D.",
                                    "@_fa": "true",
                                    "ce:surname": "Wallace",
                                    "ce:indexed-name": "Wallace D."
                                },
                                {
                                    "@seq": "5",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Mirshahidi",
                                    "ce:indexed-name": "Mirshahidi H."
                                }
                            ]},
                            "ref-sourcetitle": "Cancer Treat Res Commun"
                        },
                        "ce:source-text": "Otoukesh S, Sanchez T, Mirshahidi S, Wallace D, Mirshahidi H. ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: a clinical perspective. Cancer Treat Res Commun. 2019;20:100149."
                    },
                    {
                        "ref-fulltext": "Li, H., Lai, L., Wu, B., Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Clin Drug Investig 40 (2020), 183\u2013189.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "bib27",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85076840734",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "40"},
                                "pagerange": {
                                    "@first": "183",
                                    "@last": "189"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Li",
                                    "ce:indexed-name": "Li H."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Lai",
                                    "ce:indexed-name": "Lai L."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "B.",
                                    "@_fa": "true",
                                    "ce:surname": "Wu",
                                    "ce:indexed-name": "Wu B."
                                }
                            ]},
                            "ref-sourcetitle": "Clin Drug Investig"
                        },
                        "ce:source-text": "Li H, Lai L, Wu B. Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Clin Drug Investig. 2020;40:183-189."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Taipei",
            "@id": "60031913",
            "affilname": "Chang Gung Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031913",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Basel",
            "@id": "60009968",
            "affilname": "Novartis International AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009968",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Chengdu",
            "@id": "60073509",
            "affilname": "West China School of Medicine/West China Hospital of Sichuan University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073509",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60073385",
            "affilname": "National Taiwan University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60069718",
            "affilname": "Guangdong Provincial People\u2019s Hospital of Southern Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069718",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Taichung",
            "@id": "60031941",
            "affilname": "China Medical University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031941",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60031809",
            "affilname": "National Cancer Centre, Singapore",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031809",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60013314",
            "affilname": "Veterans General Hospital-Taipei",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013314",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Tianjin",
            "@id": "60011715",
            "affilname": "Tianjin Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011715",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60006314",
            "affilname": "Prince of Songkla University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314",
            "affiliation-country": "Thailand"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85109827725",
        "dc:description": "Introduction: In the phase 3 ASCEND-4 study, ceritinib exhibited improved progression-free survival (PFS) by Blinded Independent Review Committee (BIRC) assessment versus the standard first-line chemotherapy in patients with advanced ALK-rearranged NSCLC. Here, we assessed the efficacy and safety of ceritinib in the subgroup of Asian patients from the ASCEND-4 trial. Methods: Treatment-naive patients with stage IIIB or IV ALK-rearranged nonsquamous NSCLC were randomized in a one-to-one ratio to receive either oral ceritinib 750 mg/day (fasted) daily or intravenous chemotherapy ([cisplatin 75 mg/m2 or carboplatin area under the curve 5\u20136 plus pemetrexed 500 mg/m2] every three wk, followed by pemetrexed maintenance). The primary end point was PFS by BIRC assessment. Results: Of 376 randomized patients, 158 (42.0%) were Asian (ceritinib arm: N = 76; chemotherapy arm: N = 82). The median time from randomization to the cutoff date (June 24, 2016) was 18.3 months (range = 13.5\u201334.2) in the Asian subgroup. The median PFS (by BIRC assessment) was 26.3 months (95% confidence interval [CI]: 8.6\u2013not estimable) and 10.6 months (95% CI: 6.7\u201315.0), with an estimated 34% risk reduction in PFS (hazard ratio = 0.66, 95% CI: 0.41\u20131.05) in the ceritinib arm versus chemotherapy arm. The most common adverse events of any grade were diarrhea (85.5%), increased alanine aminotransferase and vomiting (73.7% each), and increased aspartate aminotransferase and nausea (69.7% each) in the ceritinib arm, and nausea (49.3%), vomiting (42.7%), and anemia (40.0%) in the chemotherapy arm. Conclusion: Ceritinib was effective and safe in treatment-naive Asian patients with advanced ALK-rearranged NSCLC. The findings were largely consistent with that of the overall study population.",
        "prism:coverDate": "2021-03-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85109827725",
        "dc:creator": {"author": [{
            "ce:given-name": "Daniel S.W.",
            "preferred-name": {
                "ce:given-name": "Daniel S.W.",
                "ce:initials": "D.S.W.",
                "ce:surname": "Tan",
                "ce:indexed-name": "Tan D.S.W."
            },
            "@seq": "1",
            "ce:initials": "D.S.W.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60031809",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031809"
            },
            "ce:degrees": "BSc, M.B.B.S., MRCP, PhD",
            "ce:surname": "Tan",
            "@auid": "58314382700",
            "author-url": "https://api.elsevier.com/content/author/author_id/58314382700",
            "ce:indexed-name": "Tan D.S.W."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85109827725"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85109827725&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85109827725&origin=inward"
            }
        ],
        "source-id": "21101051861",
        "pii": "S266636432030182X",
        "citedby-count": "3",
        "prism:volume": "2",
        "subtype": "ar",
        "dc:title": "Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis",
        "openaccess": "1",
        "prism:issn": "26663643",
        "publishercopyright": "© 2020",
        "article-number": "100131",
        "prism:issueIdentifier": "3",
        "subtypeDescription": "Article",
        "prism:publicationName": "JTO Clinical and Research Reports",
        "openaccessFlag": "true",
        "prism:doi": "10.1016/j.jtocrr.2020.100131",
        "dc:identifier": "SCOPUS_ID:85109827725",
        "dc:publisher": "Elsevier Inc."
    },
    "idxterms": null,
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "ALK"
        },
        {
            "@_fa": "true",
            "$": "ASCEND-4"
        },
        {
            "@_fa": "true",
            "$": "Ceritinib"
        },
        {
            "@_fa": "true",
            "$": "NSCLC"
        }
    ]},
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pulmonary and Respiratory Medicine",
            "@code": "2740",
            "@abbrev": "MEDI"
        }
    ]},
    "authors": {"author": [
        {
            "ce:given-name": "Daniel S.W.",
            "preferred-name": {
                "ce:given-name": "Daniel S.W.",
                "ce:initials": "D.S.W.",
                "ce:surname": "Tan",
                "ce:indexed-name": "Tan D.S.W."
            },
            "@seq": "1",
            "ce:initials": "D.S.W.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60031809",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031809"
            },
            "ce:degrees": "BSc, M.B.B.S., MRCP, PhD",
            "ce:surname": "Tan",
            "@auid": "58314382700",
            "author-url": "https://api.elsevier.com/content/author/author_id/58314382700",
            "ce:indexed-name": "Tan D.S.W."
        },
        {
            "ce:given-name": "Sarayut",
            "preferred-name": {
                "ce:given-name": "Sarayut",
                "ce:initials": "S.",
                "ce:surname": "Geater",
                "ce:indexed-name": "Geater S."
            },
            "@seq": "2",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60006314",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314"
            },
            "ce:degrees": "MD",
            "ce:surname": "Geater",
            "@auid": "16636219700",
            "author-url": "https://api.elsevier.com/content/author/author_id/16636219700",
            "ce:indexed-name": "Geater S."
        },
        {
            "ce:given-name": "Chong-Jen",
            "preferred-name": {
                "ce:given-name": "Chong Jen",
                "ce:initials": "C.J.",
                "ce:surname": "Yu",
                "ce:indexed-name": "Yu C.J."
            },
            "@seq": "3",
            "ce:initials": "C.-J.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60073385",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385"
            },
            "ce:degrees": "MD, PhD",
            "ce:surname": "Yu",
            "@auid": "7404977466",
            "author-url": "https://api.elsevier.com/content/author/author_id/7404977466",
            "ce:indexed-name": "Yu C.-J."
        },
        {
            "ce:given-name": "Chun-Ming",
            "preferred-name": {
                "ce:given-name": "Chun Ming",
                "ce:initials": "C.M.",
                "ce:surname": "Tsai",
                "ce:indexed-name": "Tsai C.M."
            },
            "@seq": "4",
            "ce:initials": "C.-M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60013314",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013314"
            },
            "ce:degrees": "MD",
            "ce:surname": "Tsai",
            "@auid": "7404967694",
            "author-url": "https://api.elsevier.com/content/author/author_id/7404967694",
            "ce:indexed-name": "Tsai C.-M."
        },
        {
            "ce:given-name": "Te-Chun",
            "preferred-name": {
                "ce:given-name": "Te Chun",
                "ce:initials": "T.C.",
                "ce:surname": "Hsia",
                "ce:indexed-name": "Hsia T.C."
            },
            "@seq": "5",
            "ce:initials": "T.-C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60031941",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031941"
            },
            "ce:degrees": "MD",
            "ce:surname": "Hsia",
            "@auid": "57221190351",
            "author-url": "https://api.elsevier.com/content/author/author_id/57221190351",
            "ce:indexed-name": "Hsia T.-C."
        },
        {
            "ce:given-name": "Jun",
            "preferred-name": {
                "ce:given-name": "Jun",
                "ce:initials": "J.",
                "ce:surname": "Chen",
                "ce:indexed-name": "Chen J."
            },
            "@seq": "6",
            "ce:initials": "J.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60011715",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011715"
            },
            "ce:degrees": "MD, PhD",
            "ce:surname": "Chen",
            "@auid": "56214794800",
            "author-url": "https://api.elsevier.com/content/author/author_id/56214794800",
            "ce:indexed-name": "Chen J."
        },
        {
            "ce:given-name": "Meng-Chih",
            "preferred-name": {
                "ce:given-name": "Meng Chih",
                "ce:initials": "M.C.",
                "ce:surname": "Lin",
                "ce:indexed-name": "Lin M.C."
            },
            "@seq": "7",
            "ce:initials": "M.-C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60031913",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031913"
            },
            "ce:degrees": "MD",
            "ce:surname": "Lin",
            "@auid": "8233414100",
            "author-url": "https://api.elsevier.com/content/author/author_id/8233414100",
            "ce:indexed-name": "Lin M.-C."
        },
        {
            "ce:given-name": "You",
            "preferred-name": {
                "ce:given-name": "You",
                "ce:initials": "Y.",
                "ce:surname": "Lu",
                "ce:indexed-name": "Lu Y."
            },
            "@seq": "8",
            "ce:initials": "Y.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60073509",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073509"
            },
            "ce:degrees": "MD",
            "ce:surname": "Lu",
            "@auid": "57216627663",
            "author-url": "https://api.elsevier.com/content/author/author_id/57216627663",
            "ce:indexed-name": "Lu Y."
        },
        {
            "ce:given-name": "Virote",
            "preferred-name": {
                "ce:given-name": "Virote",
                "ce:initials": "V.",
                "ce:surname": "Sriuranpong",
                "ce:indexed-name": "Sriuranpong V."
            },
            "@seq": "9",
            "ce:initials": "V.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60022183",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"
            },
            "ce:degrees": "MD",
            "ce:surname": "Sriuranpong",
            "@auid": "6603599644",
            "author-url": "https://api.elsevier.com/content/author/author_id/6603599644",
            "ce:indexed-name": "Sriuranpong V."
        },
        {
            "ce:given-name": "Cheng-Ta",
            "preferred-name": {
                "ce:given-name": "Cheng Ta",
                "ce:initials": "C.T.",
                "ce:surname": "Yang",
                "ce:indexed-name": "Yang C.T."
            },
            "@seq": "10",
            "ce:initials": "C.-T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60031913",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031913"
            },
            "ce:degrees": "MD",
            "ce:surname": "Yang",
            "@auid": "8201458000",
            "author-url": "https://api.elsevier.com/content/author/author_id/8201458000",
            "ce:indexed-name": "Yang C.-T."
        },
        {
            "ce:given-name": "Paramita",
            "preferred-name": {
                "ce:given-name": "Paramita",
                "ce:initials": "P.",
                "ce:surname": "Sen",
                "ce:indexed-name": "Sen P."
            },
            "@seq": "11",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60009968",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009968"
            },
            "ce:degrees": "PhD",
            "ce:surname": "Sen",
            "@auid": "55619668500",
            "author-url": "https://api.elsevier.com/content/author/author_id/55619668500",
            "ce:indexed-name": "Sen P."
        },
        {
            "ce:given-name": "Fabrice",
            "preferred-name": {
                "ce:given-name": "Fabrice",
                "ce:initials": "F.",
                "ce:surname": "Branle",
                "ce:indexed-name": "Branle F."
            },
            "@seq": "12",
            "ce:initials": "F.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60009968",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009968"
            },
            "ce:degrees": "MD",
            "ce:surname": "Branle",
            "@auid": "23768207500",
            "author-url": "https://api.elsevier.com/content/author/author_id/23768207500",
            "ce:indexed-name": "Branle F."
        },
        {
            "ce:given-name": "Michael",
            "preferred-name": {
                "ce:given-name": "Michael",
                "ce:initials": "M.",
                "ce:surname": "Shi",
                "ce:indexed-name": "Shi M."
            },
            "@seq": "13",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60009968",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009968"
            },
            "ce:degrees": "MD",
            "ce:surname": "Shi",
            "@auid": "57213819275",
            "author-url": "https://api.elsevier.com/content/author/author_id/57213819275",
            "ce:indexed-name": "Shi M."
        },
        {
            "ce:given-name": "Yi-Long",
            "preferred-name": {
                "ce:given-name": "Yi Long",
                "ce:initials": "Y.L.",
                "ce:surname": "Wu",
                "ce:indexed-name": "Wu Y.L."
            },
            "@seq": "14",
            "ce:initials": "Y.-L.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60069718",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069718"
            },
            "ce:degrees": "MD",
            "ce:surname": "Wu",
            "@auid": "57214815576",
            "author-url": "https://api.elsevier.com/content/author/author_id/57214815576",
            "ce:indexed-name": "Wu Y.-L."
        }
    ]}
}}